BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       


Qualyst and Solvo Biotechnology announce alliance for B CLEAR® in Europe

RALEIGH, NC. U.S.A. and Budapest, Hungary (5 December 2007)

Solvo Biotechnology, a leading provider of drug transport technologies, cell products and contract in vitro and in vivo laboratory services, and Qualyst, Inc., a leader in the development and commercialization of novel and proprietary absorption, distribution, metabolism, excretion and toxicity (ADMET) technologies, today announced that Solvo has obtained a license to Qualyst’s B‑CLEAR® system.  B-CLEAR® products and services are projected to be available in Europe from Solvo in early 2008.  Financial details were not disclosed.

B-CLEAR® is a patented system for the in vitro assessment and in vivo prediction of hepatobiliary disposition, hepatic uptake, hepatic efflux, biliary clearance and drug transport. B-CLEAR® offers research organizations the ability to generate physiologically-relevant data and enable decision making in critical areas related to hepatic transport and adverse drug interactions, helping to avoid costly drug development challenges.  B-CLEAR® can be used as an early discovery screen for promotion of compounds, as a source of lead optimization guidance, and as a tool to address development-stage drug transport and drug-drug interaction challenges.

About Qualyst, Inc.

Qualyst commercializes novel and proprietary ADMET products for drug discovery and development.  Qualyst’s products allow pharmaceutical and biotechnology researchers to make faster, better decisions regarding drug candidate compounds, saving valuable time and research dollars in the process.  For additional information, please refer to the company's web site at www.qualyst.com or call 919-313-6500.

About Solvo,

Solvo Biotechnology - "The Transporter Company" is a privately held biopharmaceutical company established in 1999 by a group of pre-eminent scientists working in the areas of ABC transporter proteins and multi-drug resistance at leading Hungarian universities. SOLVO has been the pioneer and the leader in the commercialization of Membrane Transporter technologies, including therapeutics, diagnostics and drug discovery assays. For additional information, please refer to the company's web site at www.solvo.com or email sales@solvo.com . 

QUALYST CONTACT:

Marc Sedam

Chief Business Officer

info@qualyst.com

919-313-6511

SOLVO CONTACT:

Gábor Heltovics

Business Development Director

info@solvo.com

+36-23-503 940

 

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.